Hannah Linden
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
7
7
6
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+29 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (7)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Norman Wolmark, MD
NSABP Foundation Inc
Shared therapeutic areas:
Worked with same sponsors:
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
Project Leader
Ono Pharmaceutical Co., Ltd.
Shared therapeutic areas:
Sirilak Suksompong, MD
Mahidol University
Shared therapeutic areas:
Xiaolong Qi, MD
LanZhou University
Shared therapeutic areas:
Murad Alam, MD
Northwestern University
Shared therapeutic areas:
James C Eisenach, MD
Wake Forest University Health Sciences
Shared therapeutic areas:
Charles L. Loprinzi, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Kathy S. Albain, MD
Loyola University
Shared therapeutic areas:
Worked with same sponsors:
Michael Gold, MD
Tennessee Clinical Research Center
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (7)
Showing 7 of 7 trials
Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer
Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer
Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
All 7 trials loaded